Detalhe da pesquisa
1.
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial.
Lancet Oncol
; 23(7): 876-887, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35636444
2.
Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trial.
Int J Cancer
; 151(10): 1760-1769, 2022 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35678328
3.
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?
Br J Cancer
; 127(5): 957-967, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35665778
4.
Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study.
Br J Cancer
; 126(3): 449-455, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34811502
5.
CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies.
Br J Cancer
; 125(6): 839-845, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34253871
6.
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO.
Br J Cancer
; 124(1): 183-190, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33024268
7.
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
Oncologist
; 26(4): 302-309, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33336844
8.
Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study.
Support Care Cancer
; 29(7): 3971-3980, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33392769
9.
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Lancet Oncol
; 21(4): 497-507, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32164906
10.
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials.
Br J Cancer
; 123(3): 403-409, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32424148
11.
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
BMC Cancer
; 20(1): 683, 2020 Jul 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-32698790
12.
CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer.
Br J Cancer
; 121(7): 593-599, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31474758
13.
Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?
Pharmacogenomics J
; 19(5): 465-472, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30713338
14.
Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib.
Pharmacogenomics J
; 19(5): 455-464, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30686821
15.
Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program.
Oncologist
; 23(10): 1178-1187, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29739893
16.
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients.
Invest New Drugs
; 36(4): 709-714, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29488048
17.
The Winding Roadmap of Biomarkers toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer.
Int J Mol Sci
; 19(8)2018 Aug 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30081606
18.
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab.
Br J Cancer
; 117(3): 315-321, 2017 Jul 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-28632725
19.
TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.
BMC Cancer
; 17(1): 408, 2017 Jun 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28599628
20.
Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer.
Oncologist
; 21(8): 988-94, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27382031